Work

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

Year: 2004

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-04-1187

Authors: Emiliano Calvo, Anthony W. Tolcher, Lisa A. Hammond, Amita Patnaik, Johan S. de Bono, Irene A. Eiseman, Stephen C. Olson, Peter F. Lenehan, Heather McCreery, Patricia LoRusso, Eric K. Rowinsky

Institutions: The University of Texas at San Antonio Health Science Center, Pfizer (United States), Wayne State University

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2141937666

FWCI: 5.582

Cites: 33

Cited by: 80

Related to: 10